$MIRM

Howe Jolanda sold $327K of MIRM

Howe Jolanda (SVP, GLOBAL CONTROLLER) sold 2,721 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $120.00 ($0.33M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Howe Jolanda
Published Jul 2, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MIRM
Neutral
high confidence
Mentioned
$MIRM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MIRMNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the disclosed insider selling, but 10b5-1 status typically makes it a low-signal catalyst.

03

What to watch

The article provides only one insider sale; without context on prior insider trades, total insider net activity, or company performance, signal strength is limited.

Relevance 3/10Novelty 3/10Timing: new Form 4 filed 2026-07-02 (sale dated 2026-07-01)

Background

This is an SEC Form 4 insider transaction disclosure for Mirum Pharmaceuticals, Inc. (MIRM).

Company-level read

Ticker impact

$MIRMNeutralHigh confidence
Context

Mirum Pharmaceuticals Form 4 shows SVP Global Controller Howe Jolanda sold 2,721 shares at $120 on 2026-07-01 under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely absorbed as non-informational selling.

Evidence & confidence

The filing is a disclosed open-market sale with an explicit pre-arranged 10b5-1 plan, reducing interpretive value for near-term fundamentals.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal risk management or diversification needs; monitor for clustering versus isolated sales.

Key entities

  • Mirum Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction; SVP Global Controller sold shares under a 10b5-1 plan.

  • Howe Jolanda

    SVP, Global Controller; sold 2,721 shares at $120 on 2026-07-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MIRMHighAI 8/10

Mirum will present longer-term hepatitis D response data, including in people with cirrhosis.

Mirum Pharmaceuticals will present data on its hepatitis D treatment, brelovitug, at The Liver Meeting 2026, including Phase 3 results and longer-term efficacy in patients with cirrhosis. The company will also share additional analyses on volixibat for primary sclerosing cholangitis (PSC) and new evidence on LIVMARLI (maralixibat) for rare cholestatic liver diseases.

$MIRMMedAI 8/10

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) reported positive results from Cohort 2 of the PROGRESS study for ATEBRIOZ (zilurgisertib) in pediatric FOP patients aged 6 to <12. The drug reduced HO lesion volume and improved joint mobility, with no new lesions. Mirum plans an sNDA submission in H1 2027 to expand the indication. Safety findings were consistent with prior data.

$MIRMHighAI 9/10

Mirum Pharmaceuticals Reports Positive Pediatric ATEBRIOZ Study Results

Mirum Pharmaceuticals reported positive results from a pediatric study of ATEBRIOZ, showing reduced heterotopic ossification and improved joint mobility in children aged 6 to under 12 with FOP. At Week 24, lesion volume decreased by 8.09 cm³ with zilurgisertib and increased by 9.14 cm³ with placebo. The company plans to submit an sNDA in the first half of 2027 for expanded use.

$MIRMMedAI 9/10

Mirum Pharmaceuticals, Inc. (MIRM): Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with…

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva On October 26, 2026, Mirum Pharmaceuticals, Inc. (the “Company”)